Drug intelligence / Profile preview

ana971

Development stage: Preclinical
Lead developer: Roche
Modality: Small Molecules
Administration: Oral

Overview

ANA971 is a prodrug designed to improve the oral bioavailability of isatoribine. When administered orally, ANA971 results in higher levels of isatoribine in the blood. Isatoribine is a nucleoside analog that was in development for the treatment of chronic hepatitis C virus.

Targets

TLR7 (Toll-like receptor 7)

Beyond the preview

Go deeper on ana971.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ana971.

Explore the full profile